Ann Neurol
- ALPING P, Neovius M, Piehl F, Frisell T, et al
Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label
Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting
Multiple Sclerosis: A Nationwide Cost-Effectiveness Study.
Ann Neurol. 2024 Mar 26. doi: 10.1002/ana.26914.
BMC Neurol
- KURI A, Henshall DE, Chaudhry D, Ooi SZY, et al
Delays in Multiple Sclerosis diagnosis (DIMES): protocol for a multicentre,
observational study of multiple sclerosis diagnostic pathways in the United
Kingdom and Republic of Ireland.
BMC Neurol. 2024;24:105.
Brain
- MAINERO C, Miscioscia A, Treaba CA
Cortical remyelination in multiple sclerosis: a target for disease monitoring and
intervention.
Brain. 2024 Mar 27:awae083. doi: 10.1093.
J Neurol
- GUILLEMIN C, Vandeleene N, Charonitis M, Requier F, et al
Brain microstructure is linked to cognitive fatigue in early multiple sclerosis.
J Neurol. 2024 Mar 28. doi: 10.1007/s00415-024-12316.
- SCHALLER-PAULE MA, Maiworm M, Schafer JH, Friedauer L, et al
Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to
serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
J Neurol. 2024 Mar 27. doi: 10.1007/s00415-024-12299.
- MALLUCCI G, Ferraro OE, Trojano M, Amato MP, et al
Early prediction of unfavorable evolution after a first clinical episode
suggestive of multiple sclerosis: the EUMUS score.
J Neurol. 2024 Mar 26. doi: 10.1007/s00415-024-12304.
- PILOTTO S, Floris M, Solla P, Pugliatti M, et al
Determinants of self-perceived quality of life in mildly disabled multiple
sclerosis patients: a cross-sectional study.
J Neurol. 2024 Mar 25. doi: 10.1007/s00415-024-12244.
- GOERECI Y, Ellenberger D, Rommer P, Dunkl V, et al
Persons with multiple sclerosis older than 55 years: an analysis from the German
MS registry.
J Neurol. 2024 Mar 22. doi: 10.1007/s00415-024-12286.
- TEDONE N, Vizzino C, Meani A, Gallo A, et al
The brief repeatable battery of neuropsychological tests (BRB-N) version a:
update of Italian normative data from the Italian Neuroimaging Network Initiative
(INNI).
J Neurol. 2024;271:1813-1823.
J Neurol Neurosurg Psychiatry
- KALINCIK T, Sharmin S, Roos I, Massey J, et al
Effectiveness of autologous haematopoietic stem cell transplantation versus
natalizumab in progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry. 2024 Mar 27:jnnp-2023-332790.
- VERSTEGEN NJM, Hagen RR, Kreher C, Kuijper LH, et al
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in
anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA
vaccination.
J Neurol Neurosurg Psychiatry. 2024 Mar 28:jnnp-2023-332224.
Mult Scler
- SIMPSON AC, Hu C, Mowry EM, Naismith RT, et al
Structural MRI measures are associated with fatigue severity and persistence in a
large, real-world cohort of people with multiple sclerosis.
Mult Scler. 2024 Mar 25:13524585241239473. doi: 10.1177/13524585241239473.
- SORENSEN PS, Bramow S, Magyari M, Werdelin L, et al
Torben Fog - A Danish pioneer in a multi-faceted spectrum of multiple sclerosis
research.
Mult Scler. 2024 Mar 24:13524585241239506. doi: 10.1177/13524585241239506.
- MAILLART E, Redolfi S, Louapre C, Houot M, et al
Clinical correlates of respiratory disorders in patients with severe multiple
sclerosis: A cross-sectional cohort.
Mult Scler. 2024 Mar 22:13524585241238840. doi: 10.1177/13524585241238840.
Neurology
-
Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal,
Prospective, Multicenter Study.
Neurology. 2024;102:e209214.
- PAPP V, Magyari M, Moller S, Sellebjerg F, et al
Mortality of the Danish Nationwide AQP4 Antibody-Seropositive Neuromyelitis
Optica Spectrum Disorder Patient Cohort.
Neurology. 2024;102:e209147.
PLoS One
- CARATIS F, Opielka M, Hausmann M, Velasco-Estevez M, et al
The proton-sensing receptors TDAG8 and GPR4 are differentially expressed in human
and mouse oligodendrocytes: Exploring their role in neuroinflammation and
multiple sclerosis.
PLoS One. 2024;19:e0283060.
- LEREIM RR, Nytrova P, Guldbrandsen A, Havrdova EK, et al
Natalizumab promotes anti-inflammatory and repair effects in multiple sclerosis.
PLoS One. 2024;19:e0300914.
- BRNABIC AJM, Curtis SE, Johnston JA, Lo A, et al
Incidence of type 2 diabetes, cardiovascular disease and chronic kidney disease
in patients with multiple sclerosis initiating disease-modifying therapies:
Retrospective cohort study using a frequentist model averaging statistical
framework.
PLoS One. 2024;19:e0300708.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016